What is the long-term trend for Arcus Biosciences's deferred revenue, net of current portion?

Over 5 years (2020 to 2025), Arcus Biosciences's deferred revenue, net of current portion has grown at a -20.2% compound annual growth rate (CAGR), from $132.53M to $43M.

Arcus Biosciences RCUS Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

Regeneron PharmaceuticalsREGN

$225.1M+6.3%

ExelixisEXEL

——

Kymera TherapeuticsKYMR

——

Other financials

Income statement

See full

Revenue$17.0M-39.3%

Operating income-$134.0M-9.8%

Net income-$128.0M-14.3%

EPS (diluted)-$1.02+10.5%

Balance sheet

See full

Cash & equivalents$201.0M+4.7%

Total debt$113.0M+88.3%

Total equity$524.0M-1.3%

Total assets$997.0M-13.8%

Cash flow

See full

Operating cash flow-$138.0M-4.5%

CapEx--100%

Free cash flow-$138.0M-3.8%

Valuation

See full

Market cap$3.62B+226%

Enterprise value$3.53B+275%

P/S15.4×+7.5×

Profitability

See full

Operating margin-168.6%-52.7pp

Net margin-156.4%-47.5pp

FCF margin-207.2%—

Returns & leverage

See full

Return on equity-70%+8.4pp

Debt / equity0.2×+0.1×

Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arcus Biosciences's deferred revenue, net of current portion?: Arcus Biosciences (RCUS) reported deferred revenue, net of current portion of $45M in Q1 2026.
How has Arcus Biosciences's deferred revenue, net of current portion changed year-over-year?: Arcus Biosciences's deferred revenue, net of current portion decreased by 79.5% year-over-year, from $219M to $45M.
What is the long-term trend for Arcus Biosciences's deferred revenue, net of current portion?: Over 5 years (2020 to 2025), Arcus Biosciences's deferred revenue, net of current portion has grown at a -20.2% compound annual growth rate (CAGR), from $132.53M to $43M.